News

Sapreme will present data at the RNAi-Based Therapeutics Summit, demonstrating the potential of its Endosomal Escape Enhancing compound SPT001 to enable superior targeted delivery of oligonucleotides.

June 10, 2021
Sapreme will present data at the RNAi-Based Therapeutics Summit, demonstrating the potential of its Endosomal Escape Enhancing...
Read more
Sapreme will present data at the RNAi-Based Therapeutics Summit, demonstrating the potential of its Endosomal Escape Enhancing compound SPT001 to enable superior targeted delivery of oligonucleotides.

MIMETAS wins Deshima award for Dutch-Japanese business relations

June 07, 2021
MIMETAS wins Deshima award for Dutch-Japanese business relations.
Read more
MIMETAS wins Deshima award for Dutch-Japanese business relations

Merus Presents Clinical Data on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting (Oral Abstract)

June 04, 2021
- 61 patients with NRG1+ cancer have been enrolled, including 45 patients evaluable for response as of the April 13, 2021 data...
Read more
Merus Presents Clinical Data on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting (Oral Abstract)

Macrophage Pharma Appoints Dr Venkat Reddy as Chief Executive Officer

June 01, 2021
Macrophage Pharma Limited ('MPL') announced today that its Chief Scientific Officer (CSO), Dr Venkat Reddy PhD, has been appoin...
Read more
Macrophage Pharma Appoints Dr Venkat Reddy as Chief Executive Officer

MIMETAS Opens Phenotypic Screening Center

May 27, 2021
​​​​​​​Largest reported organ-on-a-chip screen ever performed on a 3D angiogenesis assay
Read more
MIMETAS Opens Phenotypic Screening Center

ISA Pharmaceuticals Co-authors Publication in Nature Reviews Cancer on Therapeutic Cancer Vaccines

May 04, 2021
The Nature Reviews Cancer paper summarizes key insights gleaned from previous successful and non-successful therapeutic vaccine...
Read more
ISA Pharmaceuticals Co-authors Publication in Nature Reviews Cancer on Therapeutic Cancer Vaccines

Merus Announces First Patient Treated in Phase 1/2 Clinical Trial of MCLA-129 in Advanced Lung Cancer and Other Solid Tumors

May 03, 2021
First patient has been treated in its phase 1/2 dose escalation and expansion trial evaluating MCLA-129 for the treatment of pa...
Read more
Merus Announces First Patient Treated in Phase 1/2 Clinical Trial of MCLA-129 in Advanced Lung Cancer and Other Solid Tumors

ISA has relocated to brand new Biopartner 5 building

May 03, 2021
ISA has relocated to brand new Biopartner 5 building
Read more
ISA has relocated to brand new Biopartner 5 building

Modra Pharmaceuticals Appoints Two New Supervisory Board Members Adding Significant Experience in Corporate and Clinical Development

April 27, 2021
Modra Pharmaceuticals Appoints Two New Supervisory Board Members
Read more
Modra Pharmaceuticals Appoints Two New Supervisory Board Members Adding Significant Experience in Corporate and Clinical Development

InteRNA Technologies Publishes Preclinical Data from Investigational microRNA INT-1B3 Program in Molecular Therapy - Nucleic Acids and Oncotarget

March 24, 2021
Results further support the potential of lead candidate, INT-1B3, as novel option for therapeutic intervention in oncology
Read more
InteRNA Technologies Publishes Preclinical Data from Investigational  microRNA INT-1B3 Program in Molecular Therapy - Nucleic Acids and Oncotarget

InteRNA Technologies Awarded € 2.7M Clinical Innovation Credit from Dutch Government

March 11, 2021
This award will support the clinical validation of the Company's lead candidate, INT-1B3, for the treatment of solid tumors.
Read more
InteRNA Technologies Awarded € 2.7M Clinical Innovation Credit from Dutch Government

ORCA Therapeutics B.V. to Start Highest Scheduled Dose in Phase 1/2a Study of ORCA-010 in Treatment-Naïve Prostate Cancer Patients. Consistent Efficacy Data from First Cohort and Start New Indication. Additional funding secured.

March 05, 2021
ORCA Therapeutics B.V. to Start Highest Scheduled Dose in Phase 1/2a Study of ORCA-010 in Treatment-Naïve Prostate Cancer Patie...
Read more
ORCA Therapeutics B.V. to Start Highest Scheduled Dose in Phase 1/2a Study of ORCA-010 in Treatment-Naïve Prostate Cancer Patients. Consistent Efficacy Data from First Cohort and Start New Indication. Additional funding secured.

ISA Pharmaceuticals selects product candidate for clinical trial with first in class COVID-19 immunotherapy

March 03, 2021
ISA106's promising results in preclinical tests warrant fast entry into human studies to address the need for effective COVID-1...
Read more
ISA Pharmaceuticals selects product candidate for clinical trial with first in class COVID-19 immunotherapy

InteRNA Technologies Announces Dosing of First Patient in First-in-Human Trial of microRNA Drug Candidate INT-1B3 in Patients with Advanced Solid Tumors

February 16, 2021
-- Phase 1 study to investigate safety and preliminary efficacy of lead candidate, INT-1B3 --
Read more
InteRNA Technologies Announces Dosing of First Patient in  First-in-Human Trial of microRNA Drug Candidate INT-1B3 in Patients with Advanced Solid Tumors

Modra Pharmaceuticals Presents Preliminary Data from Phase IIb Trial of ModraDoc006/r in Metastatic Prostate Cancer at 2021 ASCO GU Annual Meeting

February 12, 2021
Preliminary Data from Phase IIb Trial of ModraDoc006/r in Metastatic Prostate Cancer at 2021 ASCO GU Annual Meeting
Read more
Modra Pharmaceuticals Presents Preliminary Data from Phase IIb Trial of ModraDoc006/r in Metastatic Prostate Cancer at 2021 ASCO GU Annual Meeting

InteRNA Technologies Extends Series B Financing Round Totaling EUR 18.5M

February 09, 2021
-- Proceeds to advance clinical evaluation of lead candidate INT-1B3 and further preclinical drug candidates towards the clinic --
Read more
InteRNA Technologies Extends Series B Financing Round Totaling EUR 18.5M

First Patient Treated in Phase II Combination Trial of ISA Pharmaceuticals' Lead Immunotherapy ISA101b with Keytruda®

January 26, 2021
Combination aimed at priming and driving durable patient immune responses to cancer
Read more
First Patient Treated in Phase II Combination Trial of ISA Pharmaceuticals' Lead Immunotherapy ISA101b with Keytruda®

Sapreme Appoints Henrik Luessen as Chief Business Officer

January 21, 2021
Appointment of Henrik L. Luessen, Ph.D., as Chief Business Officer at Sapreme
Read more
Sapreme Appoints Henrik Luessen as Chief Business Officer

Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies

January 19, 2021
Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Merus N.V. (NASDAQ: MRUS), a...
Read more
Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies

Merus Announces Collaborations with Nationwide Medical Organizations in the Netherlands and Japan to Enhance Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the eNRGy Clinical Trial

January 12, 2021
Merus N.V. today announced collaborations with nationwide medical organizations in the Netherlands and Japan to raise awareness...
Read more
Merus Announces Collaborations with Nationwide Medical Organizations in the Netherlands and Japan to Enhance Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the eNRGy Clinical Trial
1 2 3 4 Next

Home > News > Archive

© 2021 Aglaia Oncology Funds | Privacy | Sitemap
Aglaia Oncology Funds